{"id":23184,"date":"2023-03-16T04:43:00","date_gmt":"2023-03-15T20:43:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=23184"},"modified":"2023-03-16T05:33:54","modified_gmt":"2023-03-15T21:33:54","slug":"blue-journal%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e5%ae%b6%e5%ba%ad%e9%ab%98%e6%b5%81%e9%87%8f%e9%bc%bb%e5%af%bc%e7%ae%a1%e6%b0%a7%e7%96%97%e6%b2%bb%e7%96%97%e7%a8%b3%e5%ae%9a%e7%9a%84co2","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=23184","title":{"rendered":"[Blue Journal\u53d1\u8868\u8bba\u6587]\uff1a\u5bb6\u5ead\u9ad8\u6d41\u91cf\u9f3b\u5bfc\u7ba1\u6c27\u7597\u6cbb\u7597\u7a33\u5b9a\u7684CO2\u6f74\u7559COPD\u60a3\u8005"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial<\/h1>\n\n\n\n<h3 class=\"wp-block-heading\">Kazuma Nagata,&nbsp;Takeo Horie,&nbsp;Naohiko Chohnabayashi,&nbsp;et al<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">Am J Respir Crit Care Med 2022 Dec 1;206(11):1326-1335<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">DOI:\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/doi.org\/10.1164\/rccm.202201-0199oc\" target=\"_blank\">10.1164\/rccm.202201-0199OC<\/a><\/h3>\n\n\n\n<h2 class=\"wp-block-heading\">Abstract<\/h2>\n\n\n\n<p><strong>Rationale:<\/strong>&nbsp;The long-term effects of using a high-flow nasal cannula for chronic hypercapnic respiratory failure caused by chronic obstructive pulmonary disease remain unclear.&nbsp;<strong>Objectives:<\/strong>&nbsp;To assess whether long-term high-flow nasal cannula use reduces the number of exacerbations and improves other physiological parameters in patients with chronic hypercapnic respiratory failure caused by chronic obstructive pulmonary disease.&nbsp;<strong>Methods:<\/strong>&nbsp;We enrolled 104 participants (aged \u2a7e40 yr) with daytime hypercapnia (Global Initiative for Chronic Obstructive Lung Disease stages 2-4) receiving long-term oxygen therapy (\u2a7e16 h\/d for \u2a7e1 mo) and randomly assigned them to high-flow nasal cannula\/long-term oxygen therapy and long-term oxygen therapy groups. The primary endpoint was the moderate or severe exacerbation rate. We compared changes from baseline in arterial blood gas values, peripheral oxygen saturation, pulmonary function, health-related quality-of-life scores, and the 6-minute-walk test.&nbsp;<strong>Measurements and Main Results:<\/strong>&nbsp;High-flow nasal cannula use significantly reduced the rate of moderate\/severe exacerbations (unadjusted mean count 1.0 vs. 2.5, a ratio of the adjusted mean count between groups [95% confidence interval] of 2.85 [1.48-5.47]) and prolonged the duration without moderate or severe exacerbations. The median time to first moderate or severe exacerbation in the long-term oxygen therapy group was 25 (14.1-47.4) weeks; this was not reached in the high-flow nasal cannula\/long-term oxygen therapy group. High-flow nasal cannula use significantly improved health-related quality of life scores, peripheral oxygen saturation, and specific pulmonary function parameters. No safety concerns were identified.&nbsp;<strong>Conclusions:<\/strong>&nbsp;A high-flow nasal cannula is a reasonable therapeutic option for patients with stable hypercapnic chronic obstructive pulmonary disease and a history of exacerbations. Clinical trial registered with www.umin\/ac.jp (UMIN000028581) and www.clinicaltrials.gov (<a href=\"http:\/\/clinicaltrials.gov\/show\/NCT03282019\">NCT03282019<\/a>).<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/www.atsjournals.org\/na101\/home\/literatum\/publisher\/thoracic\/journals\/content\/ajrccm\/2022\/ajrccm.2022.206.issue-11\/rccm.202201-0199oc\/20221116\/images\/large\/rccm.202201-0199ocf1.jpeg\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/www.atsjournals.org\/na101\/home\/literatum\/publisher\/thoracic\/journals\/content\/ajrccm\/2022\/ajrccm.2022.206.issue-11\/rccm.202201-0199oc\/20221116\/images\/large\/rccm.202201-0199ocf2.jpeg\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/www.atsjournals.org\/na101\/home\/literatum\/publisher\/thoracic\/journals\/content\/ajrccm\/2022\/ajrccm.2022.206.issue-11\/rccm.202201-0199oc\/20221116\/images\/large\/rccm.202201-0199ocf3.jpeg\" alt=\"\"\/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Home High-Flow Nasal Cannula Oxygen Therapy for Stable  [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23184"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23184"}],"version-history":[{"count":4,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23184\/revisions"}],"predecessor-version":[{"id":23748,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23184\/revisions\/23748"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}